Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Nuvo Pharmaceuticals Inc
MRVFF
Healthcare
Drug Manufacturers - Specialty & Generic
Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.
ts.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (OTCQX:MRVFF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Next
(1)
•••
UglyKidStock
X
View Profile
View Bullboard History
Comment by
UglyKidStock
on Jan 04, 2023 2:09pm
RE:March 07 special meeting
MRV Dec 30th Sedar filing. https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00002418
(2126)
•••
lscfa
X
View Profile
View Bullboard History
Post by
lscfa
on Dec 30, 2022 3:17pm
March 07 special meeting
Per sedar
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(1)
•••
UglyKidStock
X
View Profile
View Bullboard History
Comment by
UglyKidStock
on Dec 28, 2022 9:59pm
RE:RE:RE:90 Day Average Weighted Price
Very shady that is was a closing time just before the holidays announcement. I'm not sure who is getting the payout for this corporate theft but literally 95 percent of the shareholders
...more
(1)
•••
Marathon11
X
View Profile
View Bullboard History
Comment by
Marathon11
on Dec 28, 2022 6:52pm
RE:RE:90 Day Average Weighted Price
And how many times during that period and preceeding that period did someone sell 500 shares through a MS account to lower the close price? Also, BB determine that the price is "fair" but
...more
(2126)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Dec 28, 2022 12:44pm
RE:90 Day Average Weighted Price
The volume is so low and inconsistent that it is irrelevant in valuing co. Date Open High Low
...more
(2126)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Dec 28, 2022 12:32pm
RE:RE:RE:RE:RE:RE:RE:Buyout
Tables of peers... $ 000 Cdn Miravo Medexus Biosyent Bloom TP 1.20
...more
(2126)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Dec 28, 2022 11:38am
RE:RE:RE:RE:RE:RE:Buyout
Bloom Burton target price of $10.00 for Biosyent implies a multiple of 10x on 2023 ebitda. https://www.bloomburton.com/research/RX20221117.pdf
(1)
•••
Marathon11
X
View Profile
View Bullboard History
Post by
Marathon11
on Dec 28, 2022 11:29am
90 Day Average Weighted Price
Also very interested in trading during this period...
(1)
•••
Marathon11
X
View Profile
View Bullboard History
Comment by
Marathon11
on Dec 28, 2022 11:26am
RE:RE:RE:RE:RE:RE:RE:RE:RE:Buyout
I'll be voting NO with my approx 125K shared. Will also have friends and family vote NO. Ridiculous.
(218)
•••
baggerx99
X
View Profile
View Bullboard History
Comment by
baggerx99
on Dec 28, 2022 11:11am
RE:RE:RE:RE:RE:RE:Buyout
Damn disgusting.....maybe a counter offer may develop from some other phrma.
(2126)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Dec 28, 2022 9:48am
RE:RE:RE:RE:RE:Buyout
Bloom Burton target price of $1.50 for Medexus implies a multiple of 7.74x on 2023 ebitda. https://www.bloomburton.com/research/MDP20221110.pdf
(2126)
•••
lscfa
X
View Profile
View Bullboard History
Post by
lscfa
on Dec 27, 2022 5:18pm
Jumped 92% today in US
$0.88 US = $1.19 Cdn. $0.88020.4229 | 92.48%Volume: 124,153 USDOTCQX MARKETPLACEDELAYED PRICEMARKET CLOSEDDECEMBER 27, 2022 2:45 PMEST
...more
(2126)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Dec 27, 2022 2:35pm
RE:RE:RE:RE:RE:RE:RE:RE:Buyout
We should all complain to mgmt and threaten a no vote. Sometimes it works.... https://stockhouse.com/news/press-releases/2020/07/30/seven-aces-and-trive-capital-amend-arrangement-agreement-to
...more
(1)
•••
UglyKidStock
X
View Profile
View Bullboard History
Comment by
UglyKidStock
on Dec 27, 2022 2:04pm
RE:RE:RE:RE:RE:RE:RE:Buyout
ir@miravohealth.com email investor relations and tell them you will vote against his attempted shareholder fraud
(2126)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Dec 26, 2022 4:33pm
RE:RE:RE:RE:RE:RE:Buyout
Bloom Burton's own report says value is $1.50/sh but they reduced it by 20% for liquidity.... We have made changes to our forecasts which result in our TP for MRV shares increasing to $1.20 (DCF:
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden